Drug releasing coatings for medical devices

• US 9,005,161 B2
• Filed: 03/18/2013
• Issued: 04/14/2015
• Est. Priority Date: 11/20/2006
• Status: Active Grant

• Current Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Original Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Inventors: Wang, Lixiao
• Primary Examiner(s): ZISKA, SUZANNE E
• Application Number:
  US13/846,143
• Publication Number:
  US 20130197431A1
• Time in Patent Office: 757 Days
• Field of Search: None
• US Class Current: 604/93.01
• CPC Class Codes: A61F 2/844 folded prior to deployment
• CPC Class Codes: A61F 2/958 Inflatable balloons for placing stents or stent-grafts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/428 Vitamins, e.g. tocopherol, riboflavin
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 29/08 Materials for coatings
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/08 Materials for coatings
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61M 2025/105 having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
• CPC Class Codes: A61M 25/10 Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00

Abstract

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.

Claims

1. A balloon catheter for delivering a therapeutic agent to a tissue, the balloon catheter being sterilized from exposure of the balloon catheter to ethylene oxide and comprising a coating layer overlying an exterior surface of a balloon, the coating layer comprising a therapeutic agent, an antioxidant and an additive, wherein:

the therapeutic agent is chosen from paclitaxel, rapamycin, or combinations thereof;

the antioxidant is butylated hydroxyanisole;

the additive is chosen from PEG-20 sorbitan monooleate, PEG-20 sorbitan monolaurate, PEG-15 2-hydroxystearate, oleth-10, oleth-20, PEG-b-PLA, dioctyl sodium sulfosuccinate, sodium dodecyl sulfonate, polyvinylpyrrolidone, PEG-35 castor oil, sorbitol, lecithin, butyral trihexyl citrate, aleuritic acid, shellolic acid, or combinations thereof; and

none of the therapeutic agent in the coating layer is hydrolyzed or oxidized.

2. The balloon catheter of claim 1, wherein the additive comprises dioctyl sodium sulfosuccinate.

3. The balloon catheter of claim 2, wherein the therapeutic agent is rapamycin.

4. The balloon catheter of claim 2, wherein the additive further comprises PEG-20 sorbitan monooleate, PEG-15 2-hydroxystearate, oleth-20, PEG-b-PLA, dioctyl sodium sulfosuccinate, polyvinylpyrrolidone, PEG-35 castor oil, sorbitol, or a combination thereof.

5. The balloon catheter of claim 4, wherein the therapeutic agent is rapamycin.

6. The balloon catheter of claim 1, wherein the additive comprises PEG-15 2-hydroxystearate.

7. The balloon catheter of claim 6, wherein the therapeutic agent is rapamycin.

8. The balloon catheter of claim 6, wherein the additive further comprises sodium dodecyl sulfonate, dioctyl sodium sulfosuccinate, PEG-b-PLA, polyvinylpyrrolidone, sorbitol, or a combination thereof.

9. The balloon catheter of claim 8, wherein the therapeutic agent is rapamycin.

10. The balloon catheter of claim 1, wherein the additive comprises polyvinylpyrrolidone and at least one additional additive selected from dioctylsodium sulfosuccinate, PEG-20 sorbitan monooleate, PEG-20 sorbitan monolaurate, PEG-35 castor oil, and lecithin.

11. The balloon catheter of claim 10, wherein the therapeutic agent is rapamycin.

12. The balloon catheter of claim 1, wherein the tissue includes tissue of one of coronary vasculature, peripheral vasculature, cerebral vasculature, esophagus, airways, sinus, trachea, colon, biliary tract, urinary tract, prostate, and brain passages.

13. The balloon catheter of claim 1, wherein the balloon catheter is selected from a perfusion balloon catheter, an infusion catheter, a cutting balloon catheter, and a scoring balloon catheter.

14. The balloon catheter of claim 1, comprising a top layer overlying the surface of the coating layer overlying the exterior surface of the balloon to reduce loss of drug during transit through a body to the target tissue.

15. The balloon catheter of claim 1, wherein the balloon catheter is capable of releasing the therapeutic agent and the additive and delivering the therapeutic agent to the tissue in about 0.1 minutes to 2 minutes.

16. The balloon catheter of claim 1, wherein the coating layer consists essentially of the therapeutic agent, the antioxidant, and the additive.

17. The balloon catheter of claim 1, wherein the concentration of the therapeutic agent in the coating layer is from 1 μ

g/mm² to 20 μ

g/mm².

18. The balloon catheter of claim 1, wherein the therapeutic agent is rapamycin and the additive is a combination of PEG-20 sorbitan monooleate and dioctyl sodium sulfosuccinate.

19. The balloon catheter of claim 18, wherein the coating layer consists essentially of the therapeutic agent, the antioxidant, and the additive.